ENANTA PHARMACEUTICALS INC
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M |
| Research and development | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M | -$109.6M |
| Interest expense | $7.7M | $10.9M | $5.1M | $0 | $0 |
| Pretax income | -$83.5M | -$117.8M | -$131.0M | -$122.2M | -$107.6M |
| Income tax expense | -$1.7M | -$1.7M | $2.8M | -$433,000 | -$28.6M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | -$79.0M |
| Balance Sheet | |||||
| Cash and equivalents | $32.3M | $37.2M | $85.4M | $44.0M | $57.2M |
| Current assets | $204.3M | $299.9M | $422.8M | $311.7M | $319.0M |
| Total assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M |
| Current liabilities | $48.6M | $57.5M | $62.8M | $29.8M | $36.2M |
| Total liabilities | $216.0M | $247.8M | $245.5M | $54.1M | $39.4M |
| Stockholders' equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$19.3M | -$78.8M | -$103.2M | -$84.8M | -$70.0M |
| Depreciation and amortization | $4.6M | $2.3M | $2.4M | $3.0M | $3.3M |
| Stock-based compensation | $18.6M | $26.8M | $28.2M | $27.0M | $21.0M |
| Capital expenditure | $12.9M | $17.9M | $9.1M | $2.1M | $750,000 |
| Free cash flow | -$32.2M | -$96.7M | -$112.2M | -$86.9M | -$70.7M |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 29.1M · Free float 81.8%
Annual filing data through FY ended September 30, 2025; float as of July 12, 2026.